Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697307 | 1.00 | ADORA3 (0.53) | ADORA3NPC1RAB9ACDK5CDK5R1 | |
| SCHEMBL16697305 | 0.79 | ALDH1A1 (0.46) | NPSR1ALDH1A1 | |
| SCHEMBL16707351 | 0.79 | ADORA3 (0.69) | ADORA3NPC1RAB9AMAPTPKM | |
| SCHEMBL16697810 | 0.78 | NPC1 (0.55) | ADORA3NPC1RAB9AMAPTNPSR1 | |
| SCHEMBL16697814 | 0.78 | NPC1 (0.55) | ADORA3NPC1RAB9AMAPTNPSR1 | |
| SCHEMBL16707357 | 0.75 | MAPT (0.64) | ADORA3NPC1RAB9AMAPTNPSR1 | |
| SCHEMBL16707354 | 0.75 | MAPT (0.49) | ADORA3NPC1RAB9AMAPTNPSR1 | |
| SCHEMBL16697866 | 0.73 | ADORA3 (0.80) | ADORA3MAPTALDH1A1 | |
| SCHEMBL16697869 | 0.73 | ADORA3 (0.80) | ADORA3MAPTALDH1A1 | |
| SCHEMBL13089370 | 0.72 | NPC1 (0.81) | NPC1RAB9ACDK5CDK5R1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | EIF2AK2, GTF3C4, GTF3C1 | ADORA3 2615/4885NPC1 922/4885RAB9A 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.